Healthcare
Sigyn Therapeutics – SUCCESS PAGE – February 26, 2025
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
The only publicly traded business accelerator and holding company in the U.S. for Nordic life science companies.
A clinical-stage precision medicine company enhancing patient outcomes through improved decision-making and personalized cancer care.
The only publicly traded business accelerator and holding company in the U.S. for Nordic life science companies.
A clinical-stage precision medicine company enhancing patient outcomes through improved decision-making and personalized cancer care.
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
OncoOne has created a diverse pipeline of treatment options for solid tumor cancers as well as inflammatory diseases including rheumatoid arthritis
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
OncoOne has created a diverse pipeline of treatment options for solid tumor cancers as well as inflammatory diseases including rheumatoid arthritis
Bryn is developing a new epinephrine nasal spray that improves on the EpiPen in a number of ways. Most importantly, there are no needles.
Bryn is developing a new epinephrine nasal spray that improves on the EpiPen in a number of ways. Most importantly, there are no needles.